FINWIRES · TerminalLIVE
FINWIRES

Top Cryptocurrencies Fall; Bitcoin Drops Below $81,000

By

Top cryptocurrencies were weaker Tuesday, with Bitcoin (BTC-USD) falling below the $81,000 level.

The CoinDesk Market Index, which tracks dozens of digital assets including Bitcoin, fell almost 1.8% in the past 24 hours. The Nasdaq 100 fell 0.9%, the S&P 500 declined 0.1%, and the Dow Jones Industrial Average rose 0.2%.

Bitcoin fell 1.4% to $80,798, according to CoinMarketCap data. The most popular cryptocurrency's 24-hour trading volume dropped 16.3 % to $32.19 billion.

Ethereum (ETH-USD), the second-largest digital asset by market value, fell 2.4% to $2,283.

XRP (XRP-USD) dipped 2.5%, BNB (BNB-USD) shed 0.1%, and Solana (SOL-USD) lost 3.4%. Dogecoin (DOGE-USD) dropped 1.4%, and Cardano (ADA-USD) down 3.1%.

The US 10-year Treasury yield stood at 4.462% at 3 p.m. ET Tuesday, up from 4.408% Monday, while the five-year yield rose to 4.122% from 4.066%.

The total market value of the cryptocurrency industry fell 1.5% in the past 24 hours to $2.69 trillion, with trading volume declining 1.7% to $163.49 billion.

Price: $80812.48, Change: $-908.93, Percent Change: -1.11%

Related Articles

Australia

Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug

Gyre Therapeutics Inc (GYRE) said China's regulator accepted its new drug application for F351, a treatment for chronic hepatitis B-induced liver fibrosis.The application, which received priority review status in March, marks "a significant milestone" in the program's path toward commercialization, the company said Tuesday in a statement.In the US, Gyre has completed a Phase 1 trial evaluating the drug's safety and tolerability in healthy volunteers and plans to file an investigational new drug application by the end of 2026, with a Phase 2 trial to follow if cleared.Gyre shares rose 1.4% in after-hours trading.

$GYRE
Australia

Evolution Petroleum Swings to Fiscal Q3 Loss as Revenue Falls; Shares Drop After Hours

Evolution Petroleum (EPM) reported a fiscal Q3 adjusted loss late Tuesday of $0.09 per diluted share, swinging from earnings of $0.02 a year earlier.Analysts polled by FactSet expected earnings of $0.02.Revenue in the three months ended March 31 fell to $20.2 million from $22.6 million a year earlier.Analysts surveyed by FactSet expected $21.3 million.Evolution shares fell 7.3% in after-hours trading.

$EPM
Australia

Arteris Q1 Adjusted Loss Narrows, Revenue Rises; Shares Gain After Hours; CFO to Retire

Arteris (AIP) reported a Q1 adjusted loss late Tuesday of $0.03 per diluted share, narrowing from the loss of $0.09 a year earlier.Four analysts polled by FactSet expected a loss of $0.07.Revenue in the three months ended March 31 rose to $22.9 million from $16.5 million a year earlier.Four analysts surveyed by FactSet expected $21 million.The company expects revenue of $23 million to $24 million in Q2 and $91 million to $95 million in the full year. Four analysts expect $22 million in Q2 and $91 million in the full year.Arteris shares rose 7.9% in after-hours trading.The company also said Chief Financial Officer Nicholas Hawkins plans to retire effective Aug. 31, and the board has started a search for a new CFO.

$AIP